FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1849683091> ?p ?o ?g. }

• W1849683091 abstract "Postmenopausal osteoporosis results in an increased susceptibility to low-trauma fractures due to reduced bone volume and microarchitectural deterioration. Risedronate, a third generation bisphosphonate, has been shown in multiple clinical trials to reduce fracture risk and improve bone mineral density in postmenopausal women with osteoporosis. First and second generation bisphosphonates are known to have gastrointestinal side-effects and risedronate may be better tolerated.To systematically review the efficacy of risedronate on bone density, and fracture reduction in postmenopausal women.The Cochrane Controlled Trials Registry Medline, and Current Contents were searched from 1990 - 2001. The electronic search was supplemented by handsearching four osteoporosis journals and their conference proceedings, as well as contacting content experts and industry sources for unpublished data.We included eight trials that randomised women to risedronate or an alternative (placebo or calcium and /or vitamin D) and measured bone mineral density for at least one year.For each trial three independent reviewers assessed the methodological quality and abstracted data. Data was extracted for outcomes of fracture, bone mineral density and adverse events. The more conservative random effects model was used to pool data. The quality of trials was assessed according to the Jadad five-point scale.Both vertebral and non-vertebral fractures were statistically and clinically reduced with risedronate. Eleven out of one hundred women who received risedronate had a vertebral fracture compared to 17 out of one hundred of those who received an alternative treatment (pooled relative risk for vertebral fractures of 0.64 (95% CI 0.52 - 0.77). Three percent of participants who received risedronate had a non-vertebral fracture compared to 4.6% of those who received an alternative treatment (pooled relative risk for nonvertebral fractures of 0.73 (95% CI 0.61 - 0.87). The weighted mean difference for the percent change from baseline for bone mineral density with 5 mg daily for lumbar spine, femoral neck and trochanter was 4.54% (95%CI 4.12 - 4.97), p<0.01; 2.75% (95% CI 2.32 - 3.17), p<0.01; and 4.38% (95% CI 3.51 - 5.25), p<0.01 respectively.There is good evidence for the efficacy of risedronate in the reduction of both vertebral and non-vertebral fractures. In addition, there is evidence from randomized trials that risedronate is able to achieve this without increasing risk for overall withdrawals due to adverse effects." @default.
• W1849683091 created "2016-06-24" @default.
• W1849683091 creator A5010370021 @default.
• W1849683091 creator A5010437603 @default.
• W1849683091 creator A5022067453 @default.
• W1849683091 creator A5031717153 @default.
• W1849683091 creator A5035644440 @default.
• W1849683091 creator A5059733353 @default.
• W1849683091 creator A5059955804 @default.
• W1849683091 creator A5060799862 @default.
• W1849683091 creator A5062747501 @default.
• W1849683091 creator A5065582919 @default.
• W1849683091 creator A5068779654 @default.
• W1849683091 date "2003-10-20" @default.
• W1849683091 modified "2023-09-24" @default.
• W1849683091 title "Risedronate for the prevention and treatment of postmenopausal osteoporosis." @default.
• W1849683091 cites W1526826623 @default.
• W1849683091 cites W1530232666 @default.
• W1849683091 cites W1966064911 @default.
• W1849683091 cites W1986215651 @default.
• W1849683091 cites W2030223911 @default.
• W1849683091 cites W2036125852 @default.
• W1849683091 cites W2039548369 @default.
• W1849683091 cites W2040645421 @default.
• W1849683091 cites W2069362785 @default.
• W1849683091 cites W2102123887 @default.
• W1849683091 cites W2105788132 @default.
• W1849683091 cites W2114358979 @default.
• W1849683091 cites W2124527463 @default.
• W1849683091 cites W2148849217 @default.
• W1849683091 cites W2481651559 @default.
• W1849683091 doi "https://doi.org/10.1002/14651858.cd004523" @default.
• W1849683091 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14584020" @default.
• W1849683091 hasPublicationYear "2003" @default.
• W1849683091 type Work @default.
• W1849683091 sameAs 1849683091 @default.
• W1849683091 citedByCount "30" @default.
• W1849683091 countsByYear W18496830912012 @default.
• W1849683091 countsByYear W18496830912014 @default.
• W1849683091 countsByYear W18496830912015 @default.
• W1849683091 countsByYear W18496830912017 @default.
• W1849683091 countsByYear W18496830912021 @default.
• W1849683091 countsByYear W18496830912022 @default.
• W1849683091 crossrefType "reference-entry" @default.
• W1849683091 hasAuthorship W1849683091A5010370021 @default.
• W1849683091 hasAuthorship W1849683091A5010437603 @default.
• W1849683091 hasAuthorship W1849683091A5022067453 @default.
• W1849683091 hasAuthorship W1849683091A5031717153 @default.
• W1849683091 hasAuthorship W1849683091A5035644440 @default.
• W1849683091 hasAuthorship W1849683091A5059733353 @default.
• W1849683091 hasAuthorship W1849683091A5059955804 @default.
• W1849683091 hasAuthorship W1849683091A5060799862 @default.
• W1849683091 hasAuthorship W1849683091A5062747501 @default.
• W1849683091 hasAuthorship W1849683091A5065582919 @default.
• W1849683091 hasAuthorship W1849683091A5068779654 @default.
• W1849683091 hasConcept C126322002 @default.
• W1849683091 hasConcept C136524200 @default.
• W1849683091 hasConcept C142724271 @default.
• W1849683091 hasConcept C1862650 @default.
• W1849683091 hasConcept C197934379 @default.
• W1849683091 hasConcept C204787440 @default.
• W1849683091 hasConcept C27081682 @default.
• W1849683091 hasConcept C2776478404 @default.
• W1849683091 hasConcept C2776541429 @default.
• W1849683091 hasConcept C2776886416 @default.
• W1849683091 hasConcept C2777251235 @default.
• W1849683091 hasConcept C2779329777 @default.
• W1849683091 hasConcept C535046627 @default.
• W1849683091 hasConcept C71924100 @default.
• W1849683091 hasConcept C95190672 @default.
• W1849683091 hasConceptScore W1849683091C126322002 @default.
• W1849683091 hasConceptScore W1849683091C136524200 @default.
• W1849683091 hasConceptScore W1849683091C142724271 @default.
• W1849683091 hasConceptScore W1849683091C1862650 @default.
• W1849683091 hasConceptScore W1849683091C197934379 @default.
• W1849683091 hasConceptScore W1849683091C204787440 @default.
• W1849683091 hasConceptScore W1849683091C27081682 @default.
• W1849683091 hasConceptScore W1849683091C2776478404 @default.
• W1849683091 hasConceptScore W1849683091C2776541429 @default.
• W1849683091 hasConceptScore W1849683091C2776886416 @default.
• W1849683091 hasConceptScore W1849683091C2777251235 @default.
• W1849683091 hasConceptScore W1849683091C2779329777 @default.
• W1849683091 hasConceptScore W1849683091C535046627 @default.
• W1849683091 hasConceptScore W1849683091C71924100 @default.
• W1849683091 hasConceptScore W1849683091C95190672 @default.
• W1849683091 hasLocation W18496830911 @default.
• W1849683091 hasLocation W18496830912 @default.
• W1849683091 hasOpenAccess W1849683091 @default.
• W1849683091 hasPrimaryLocation W18496830911 @default.
• W1849683091 hasRelatedWork W1900305254 @default.
• W1849683091 hasRelatedWork W1957232404 @default.
• W1849683091 hasRelatedWork W2000209535 @default.
• W1849683091 hasRelatedWork W2042007405 @default.
• W1849683091 hasRelatedWork W2338173161 @default.
• W1849683091 hasRelatedWork W2390696564 @default.
• W1849683091 hasRelatedWork W2392373393 @default.
• W1849683091 hasRelatedWork W2430979212 @default.
• W1849683091 hasRelatedWork W2910339983 @default.
• W1849683091 hasRelatedWork W2972634484 @default.
• W1849683091 isParatext "false" @default.

• next